BCG Vaccination Complications and Management

Introduction to BCG Vaccination Complications

The Centers for Disease Control and Prevention recommends that a red and enlarged BCG vaccination site at 4 months post-vaccination be evaluated for severe local reaction or early manifestation of BCG osteitis or disseminated infection 1, 2

Standard local reactions, such as induration, pustule formation, and lymphadenopathy, typically persist for up to 3 months after vaccination, according to the Centers for Disease Control and Prevention 1, 2
Reactions beyond 3 months warrant careful evaluation for complications, as stated by the Centers for Disease Control and Prevention 1

Ulceration at the vaccination site, regional suppurative lymphadenitis, caseous lesions, or purulent drainage can occur within 5 months of vaccination and persist for several weeks, as reported by the Centers for Disease Control and Prevention 1, 2, 3
Erythema and induration are common components of these reactions, according to the Centers for Disease Control and Prevention 2, 4

BCG osteitis affecting the epiphyses of long bones can occur from 4 months to 2 years after vaccination, with a risk varying by country, as stated by the Centers for Disease Control and Prevention 1, 2, 4
Fatal disseminated BCG disease occurs at 0.06-1.56 cases per million doses, primarily in immunocompromised persons, according to the Centers for Disease Control and Prevention 1, 5

HIV infection significantly increases the risk for lymphadenitis and disseminated complications, as reported by the Centers for Disease Control and Prevention 1, 4, 5
Subcutaneous injection rather than intradermal injection increases rates of local reactions, according to the Centers for Disease Control and Prevention 1, 2, 3

The World Health Organization recommends evaluating for systemic symptoms, such as fever, bone pain, joint swelling, or signs of disseminated infection, in patients with suspected BCG complications 1, 4
The World Health Organization also recommends assessing immunocompetent status, including HIV testing if not previously done, particularly if risk factors are present 4, 5, 6
For isolated local reactions, nonadherent lymph nodes heal spontaneously without treatment, while adherent or fistulated lymph nodes may require drainage and direct instillation of anti-TB drug into the lesion, as stated by the World Health Organization 2, 4, 5
For suspected disseminated disease, anti-TB therapy is recommended, and it is critical to note that all BCG strains are resistant to pyrazinamide, which should not be used, according to the Centers for Disease Control and Prevention 1, 4, 5

Persistent reactions at 4 months should not be dismissed as normal and require evaluation for complications, as stated by the Centers for Disease Control and Prevention 1, 2
Pyrazinamide should never be used in BCG-related infections due to universal resistance, according to the Centers for Disease Control and Prevention 1, 4, 5
HIV testing should be considered in any patient with prolonged or severe BCG reactions, as immunocompromised status dramatically increases complication risk, as reported by the Centers for Disease Control and Prevention 4, 5, 6

For a localized BCG site fistula, the standard anti‑tuberculous regimen should be administered for 3 months; however, the course may need to be extended to 15 months or longer depending on the severity of symptoms and the patient’s clinical response. 7